Use of Anticholinergic Drugs in Patients with Schizophrenia in Asia from 2001 to 2009

 

 Buy Article Permissions and Reprints

Abstract

Objective: The aim of this study was to survey the use of anticholinergic medication (ACM) in Asia between 2001 and 2009 and examine its demographic and clinical correlates.

Method: A total of 6 761 hospitalized schizophrenia patients in 9 Asian countries and territories were examined between 2001 and 2009. The patients’ socio-demographic and clinical characteristics and the prescriptions of psychotropic drugs were recorded using a standardized protocol and data collection procedure.

Results: The frequency of ACM prescription decreased from 66.3% in 2001, to 52.8% in 2004 and 54.6% in 2009, with wide inter-country variations at each time period. Multiple logistic regression analysis of the whole sample showed that patients taking ACM presented with more severe positive, negative, and extrapyramidal symptoms. They were also more likely to receive first-generation and depot antipsychotics and antipsychotic polypharmacy, and less likely to receive second-generation ones.

Conclusions: The wide variation in ACM prescription across Asia suggests that a combination of clinical, social, economic and cultural factors play a role in determining the use of these drugs. Regular reviews of ACM use are desirable to reveal the discrepancy between treatment guidelines and clinical practice.

References

• 1 Carnahan RM, Lund BC, Perry PJ. et al . Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy.  Acta Psychiatr Scand. 2006;  113 135-141
  CrossrefPubMedGoogle Scholar
• 2 Lavin MR, Rifkin A. Prophylactic antiparkinson drug use: II. Withdrawal after long-term maintenance therapy.  J Clin Pharmacol. 1991;  31 769-777
  PubMedGoogle Scholar
• 3 Ungvari GS, Chiu HF, Lam LC. et al . Gradual withdrawal of long-term anticholinergic antiparkinson medication in Chinese patients with chronic schizophrenia.  J Clin Psychopharmacol. 1999;  19 141-148
  CrossrefPubMedGoogle Scholar
• 4 Brebion G, Bressan RA, Amador X. et al . Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs.  Psychol Med. 2004;  34 369-374
  CrossrefPubMedGoogle Scholar
• 5 Minzenberg MJ, Poole JH, Benton C. et al . Association of anticholinergic load with impairment of complex attention and memory in schizophrenia.  Am J Psychiatry. 2004;  161 116-124
  CrossrefPubMedGoogle Scholar
• 6 Land W, Pinsky D, Salzman C. Abuse and misuse of anticholinergic medications.  Hosp Community Psychiatry. 1991;  42 580-581
  PubMedGoogle Scholar
• 7 Longo VG. Behavioral and electroencephalographic effects of atropine and related compounds.  Pharmacol Rev. 1966;  18 965-996
  PubMedGoogle Scholar
• 8 Tandon R, Greden JF. Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia.  Arch Gen Psychiatry. 1989;  46 745-753
  CrossrefPubMedGoogle Scholar
• 9 Perris C, Dimitrijevic P, Jacobsson L. et al . Tardive dyskinesia in psychiatric patients treated with neuroleptics.  Br J Psychiatry. 1979;  135 509-514
  CrossrefPubMedGoogle Scholar
• 10 Goff DC, Arana GW, Greenblatt DJ. et al . The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial.  J Clin Psychopharmacol. 1991;  11 106-112
  PubMedGoogle Scholar
• 11 Vagen R, Gotestam KG. An experimental evaluation of the euphoric properties of antiparkinson drugs on psychotic patients.  Acta Psychiatr Scand. 1986;  74 519-523
  CrossrefPubMedGoogle Scholar
• 12 Chiu HF, Shum PS, Lam CW. Psychotropic drug prescribing to chronic schizophrenics in a Hong Kong hospital.  Int J Soc Psychiatry. 1991;  37 187-191
  CrossrefPubMedGoogle Scholar
• 13 Frackiewicz EJ, Sramek JJ, Herrera JM. et al . Ethnicity and antipsychotic response.  Ann Pharmacother. 1997;  31 1360-1369
  PubMedGoogle Scholar
• 14 Sim K, Su A, Fujii S. et al . Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia.  Br J Clin Pharmacol. 2004;  58 178-183
  CrossrefPubMedGoogle Scholar
• 15 Chong MY, Tan CH, Fujii S. et al . Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change.  Psychiatry Clin Neurosci. 2004;  58 61-67
  CrossrefPubMedGoogle Scholar
• 16 Shinfuku N, Tan CH. Pharmacotherapy for schizophrenic inpatients in East Asia – changes and challenges.  Int Rev Psychiatry. 2008;  20 460-468
  CrossrefPubMedGoogle Scholar
• 17 APA .Practice Guideline for the Treatment of Patients with Schizophrenia.. Washington, DC, American Psychiatric Press; 1997
  Google Scholar
• 18 Kane JM, Aguglia E, Altamura AC. et al . Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy.  Eur Neuropsychopharmacol. 1998;  8 55-66
  CrossrefPubMedGoogle Scholar
• 19 Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics.  J Clin Psychiatry. 2003;  64 663-667
  CrossrefPubMedGoogle Scholar
• 20 WHO . Collaborating Centre for Drug Statistic Methodology: Guidelines for ATC Index with DDDs.  Oslo, WHO, 2002; 
  PubMedGoogle Scholar
• 21 Chong MY, Tan CH, Shinfuku N. et al . Prescribing antipsychotic drugs for inpatients with schizophrenia in Asia: Comparison of REAP-2001 and REAP-2004 studies.  Asia-Pacific Psychiatry. 2010;  2 77-84
  PubMedGoogle Scholar
• 22 Chong SA, Sachdev P, Mahendran R. et al . Neuroleptic and anticholinergic drug use in Chinese patients with schizophrenia resident in a state psychiatric hospital in Singapore.  Aust N Z J Psychiatry. 2000;  34 988-991
  CrossrefPubMedGoogle Scholar
• 23 Wu RW. The combination of antipsychotics and anticholinergic medication.  Chin Clin Doct. 2001;  29 33-34
  PubMedGoogle Scholar
• 24 Lin KM, Finder E. Neuroleptic dosage for Asians.  Am J Psychiatry. 1983;  140 490-491
  PubMedGoogle Scholar
• 25 Zhang-Wong J, Beiser M, Zipursky RB. et al . An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol.  Psychiatry Res. 1998;  81 333-339
  CrossrefPubMedGoogle Scholar
• 26 Binder RL, Kazamatsuri H, Nishimura T. et al . Tardive dyskinesia and neuroleptic-induced parkinsonism in Japan.  Am J Psychiatry. 1987;  144 1494-1496
  PubMedGoogle Scholar
• 27 Gray R, Gournay K. What can we do about acute extrapyramidal symptoms?.  J Psychiatr Ment Health Nurs. 2000;  7 205-211
  CrossrefPubMedGoogle Scholar
• 28 Phillips MR, Lu SH, Wang RW. Economic reforms and the acute inpatient care of patients with schizophrenia: the Chinese experience.  Am J Psychiatry. 1997;  154 1228-1234
  PubMedGoogle Scholar
• 29 Double DB, Warren GC, Evans M. et al . Efficacy of maintenance use of anticholinergic agents.  Acta Psychiatr Scand. 1993;  88 381-384
  CrossrefPubMedGoogle Scholar
• 30 Kane JM, Evans DL, Fiester SJ. et al . Psychopharmacological screening criteria. APA Committee on Research on Psychiatric Treatments.  J Clin Psychiatry. 1992;  53 184-196
  PubMedGoogle Scholar
• 31 NICE .Schizophrenia. Full National Clinical Guideline on Core Intervention in Primary and Secondary Care.. Trowbridge, Wiltshire, UK. (also: http://www.nice.org.uk/guidance/CG1/guidance/pdf/English) Cromwell Press; 2003
  Google Scholar
• 32 WHO . Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. A consensus statement. World Health Organization heads of centres collaborating in WHO co-ordinated studies on biological aspects of mental illness.  Br J Psychiatry. 1990;  156 412
  CrossrefPubMedGoogle Scholar
• 33 Work Group on Schizophrenia .Practice Guideline for the Treatment of Patients with Schizophrenia. Second Edition.. APA Practice Guidelines. Washington, DC, American Psychiatric Press; 2004
  Google Scholar
• 34 Sim K, Su HC, Fujii S. et al . High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies.  Br J Clin Pharmacol. 2009;  67 110-117
  CrossrefPubMedGoogle Scholar
• 35 Xiang YT, Weng YZ, Leung CM. et al . Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia.  Pharmacopsychiatry. 2007;  40 47-52
  Article in Thieme ConnectPubMedGoogle Scholar
• 36 Greil W, Haag H, Rossnagl G. et al . Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study.  Br J Psychiatry. 1984;  145 304-310
  CrossrefPubMedGoogle Scholar
• 37 Dayalu P, Chou KL. Antipsychotic-induced extrapyramidal symptoms and their management.  Expert Opin Pharmacother. 2008;  9 1451-1462
  CrossrefPubMedGoogle Scholar
• 38 Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines.. London, Martin Dunitz; 2003
  Google Scholar
• 39 Xiang YT, Weng YZ, Leung CM. et al . Exploring the clinical and social determinants of prescribing anticholinergic medication for Chinese patients with schizophrenia.  Hum Psychopharmacol. 2007;  22 173-180
  CrossrefPubMedGoogle Scholar
• 40 Leucht S, Wahlbeck K, Hamann J. et al . New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.  Lancet. 2003;  361 1581-1589
  CrossrefPubMedGoogle Scholar

Correspondence

Dr. Y.-T. Xiang

Department of Psychiatry

Chinese University of

Hong Kong

Ground Floor, Multicentre

Tai Po Hospital

Tai Po, N.T.

Hong Kong

People's Republic of China

Phone: +852/2607/6041

Fax: +852/2647/5321

Email: xyutly@gmail.com

Dr. Tian-Mei Si

Peking University Institute of

Mental Health

Beijing

People's Republic of China

Phone: + 8610/8280/1948

Fax: +8610/6235/2880

Email: si.tian-mei@163.com